EUVIMEDEUVIMED entdecken
Kommentar

Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis

Xiaojing Wang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00263 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Xiaojing Wang. Beteiligte Einrichtung: Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Receptors, Lysophosphatidic Acid. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite significant advancements in the treatment options for idiopathic pulmonary fibrosis (IPF), the disease remains aggressive and incurable. This viewpoint summarizes the discovery of a neutral, potent, and selective lysophosphatidic acid receptor 1 antagonist for the treatment of IPF. The lead optimization without the cocrystal structure guidance is worth it to highlight.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisReceptors, Lysophosphatidic AcidHumansAnimalsStructure-Activity Relationship

Substanzen

Receptors, Lysophosphatidic AcidLPAR1 protein, human

Autor:innen und Institutionen

  • Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.

ORCID-Profile: Xiaojing Wang

Zitieren

APA

Wang, X. (2025). Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00263

Vancouver

Wang X. Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00263

BibTeX
@article{Wang2025,
  author = {Wang, Xiaojing},
  title = {Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00263}
}
Kostenlos starten →